文献速递心血管技术与安全CTPET

18F-GP1正电子发射断层显像与生物主动脉瓣血栓

18F-GP1 Positron Emission Tomography and Bioprosthetic Aortic Valve Thrombus.
PubMed 文献 · JACC Cardiovasc Imaging · 2022-01-12

研究以新型糖蛋白IIb/IIIa受体放射性示踪剂18F-GP1 PET-CT检测生物主动脉瓣血栓,体外实验显示其选择性结合活化血小板,75例受试者中生物瓣均见局灶性摄取且高于正常自体瓣,梗阻性血栓抗凝后摄取降低。

要点

  • 生物主动脉瓣可见局灶性18F-GP1摄取,中位最大靶本比2.81,正常自体瓣为1.43。
  • 3例梗阻性瓣血栓抗凝3个月后症状、平均瓣压差及18F-GP1摄取均改善。
  • 瓣植入时间与低衰减瓣叶增厚与更高18F-GP1摄取独立相关。

核心结论

  • 活化血小板黏附是生物主动脉瓣常见且持续存在的表现,18F-GP1摄取在血栓存在时更高、抗凝后消退,有潜力作为辅助临床工具。

研究设计与样本

  • 前瞻性横断面研究,共纳入75例受试者,其中生物瓣53例(植入中位时间37个月,IQR 12-80个月)、正常自体主动脉瓣22例,均行超声心动图、CT血管造影和18F-GP1 PET-CT;另进行人血小板及取出的生物瓣体外实验。

关键影像表现/征象

  • 所有生物瓣均见瓣叶局灶性18F-GP1摄取,正常自体瓣均无摄取。
  • 生物瓣中位最大靶本比2.81(IQR 2.29-3.48),正常自体瓣1.43(IQR 1.28-1.53),P < 0.001。
  • 3例有梗阻性瓣血栓,另3例CT血管造影见无症状低衰减瓣叶增厚。

诊断标准与关键数值

  • 18F-GP1 PET-CT以瓣叶局灶性摄取及最大靶本比评估,生物瓣中位2.81 vs 正常自体瓣1.43(P < 0.001)。
  • CT血管造影用于识别低衰减瓣叶增厚。

临床应用与阅片要点

  • 作者认为18F-GP1摄取有潜力作为辅助临床工具。
  • 3例梗阻性瓣血栓患者接受抗凝3个月后症状缓解、平均瓣压差改善、18F-GP1摄取降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Bioprosthetic valve thrombosis may have implications for valve function and durability.

OBJECTIVES: Using a novel glycoprotein IIb/IIIa receptor radiotracer 18F-GP1, we investigated whether positron emission tomography (PET)-computed tomography (CT) could detect thrombus formation on bioprosthetic aortic valves.

METHODS: Ex vivo experiments were performed on human platelets and explanted bioprosthetic aortic valves. In a prospective cross-sectional study, patients with either bioprosthetic or normal native aortic valves underwent echocardiography, CT angiography, and 18F-GP1 PET-CT.

RESULTS: Flow cytometric analysis, histology, immunohistochemistry, and autoradiography demonstrated selective binding of 18F-GP1 to activated platelet glycoprotein IIb/IIIa receptors and thrombus adherent to prosthetic valves. In total, 75 participants were recruited: 53 with bioprosthetic valves (median time from implantation 37 months [IQR: 12-80 months]) and 22 with normal native aortic valves. Three participants had obstructive valve thrombosis, and a further 3 participants had asymptomatic hypoattenuated leaflet thickening on CT angiography. All bioprosthetic valves, but none of the native aortic valves, demonstrated focal 18F-GP1 uptake on the valve leaflets: median maximum target-to-background ratio 2.81 (IQR: 2.29-3.48) vs 1.43 (IQR: 1.28-1.53) (P < 0.001). Higher 18F-GP1 uptake was independently associated with duration of valve implantation and hypoattenuated leaflet thickening. All 3 participants with obstructive valve thrombosis were anticoagulated for 3 months, leading to resolution of their symptoms, improvement in mean valve gradients, and a reduction in 18F-GP1 uptake.

CONCLUSIONS: Adherence of activated platelets is a common and sustained finding on bioprosthetic aortic valves. 18F-GP1 uptake is higher in the presence of thrombus, regresses with anticoagulation, and has potential use as an adjunctive clinical tool. (18F-GP1 PET-CT to Detect Bioprosthetic Aortic Valve Thrombosis; NCT04073875).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Bing, Deutsch, Sellers, et al. 18F-GP1 Positron Emission Tomography and Bioprosthetic Aortic Valve Thrombus. JACC Cardiovasc Imaging. 2022. PMID: 35033495. doi:10.1016/j.jcmg.2021.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。